Scholars@Duke
Journal cover image

Novel therapies are changing treatment paradigms in metastatic prostate cancer.

Publication ,  Journal Article
Powers, E; Karachaliou, GS; Kao, C; Harrison, MR; Hoimes, CJ; George, DJ; Armstrong, AJ; Zhang, T
Published in: J Hematol Oncol
October 28, 2020
Published version (DOI) Link to item

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.

Duke Scholars

Michael Roger Harrison
Author Michael Roger Harrison Medicine, Medical Oncology
Christopher Hoimes
Author Christopher Hoimes Medicine, Medical Oncology
Daniel James George
Author Daniel James George Medicine, Medical Oncology
Andrew John Armstrong
Author Andrew John Armstrong Medicine, Medical Oncology
Tian Zhang
Author Tian Zhang Medicine, Medical Oncology
Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Hematol Oncol

DOI

10.1186/s13045-020-00978-z

EISSN

1756-8722

Publication Date

October 28, 2020

Volume

13

Issue

1

Start / End Page

144

Location

England

Related Subject Headings

  • Radioisotopes
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Neoplasm Metastasis
  • Male
  • Lutetium
  • Humans
  • Heterocyclic Compounds, 1-Ring
  • Dipeptides
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Powers, E., Karachaliou, G. S., Kao, C., Harrison, M. R., Hoimes, C. J., George, D. J., … Zhang, T. (2020). Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol, 13(1), 144. https://doi.org/10.1186/s13045-020-00978-z
Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, et al. Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol. 2020 Oct 28;13(1):144.
Powers, Eric, et al. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol, vol. 13, no. 1, Oct. 2020, p. 144. Pubmed, doi:10.1186/s13045-020-00978-z.
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, Armstrong AJ, Zhang T. Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol. 2020 Oct 28;13(1):144.
Journal cover image

Published In

J Hematol Oncol

DOI

10.1186/s13045-020-00978-z

EISSN

1756-8722

Publication Date

October 28, 2020

Volume

13

Issue

1

Start / End Page

144

Location

England

Related Subject Headings

  • Radioisotopes
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Neoplasm Metastasis
  • Male
  • Lutetium
  • Humans
  • Heterocyclic Compounds, 1-Ring
  • Dipeptides